Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-lable, single-center, phase IA study to assess safety, tolerance, pharmacokinetics and efficacy of oral dosing icotinib hydrochloride tablets in various cancer patients,mainly in NSCLC.

Next Previous
Trial Profile

An open-lable, single-center, phase IA study to assess safety, tolerance, pharmacokinetics and efficacy of oral dosing icotinib hydrochloride tablets in various cancer patients,mainly in NSCLC.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotinib (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 21 May 2012 Actual end date changed from May 2009 to 31 Dec 2009 as reported by Chinese Clinical Trial Register.
  • 21 May 2012 Actual initiation date changed from Dec 2007 to Nov 2007 as reported by Chinese Clinical Trial Register.
  • 21 May 2012 Trial phase changed from I to I/II as reported by Chinese Clinical Trial Register.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top